JP7068827B2 - 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用 - Google Patents

炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用 Download PDF

Info

Publication number
JP7068827B2
JP7068827B2 JP2017568408A JP2017568408A JP7068827B2 JP 7068827 B2 JP7068827 B2 JP 7068827B2 JP 2017568408 A JP2017568408 A JP 2017568408A JP 2017568408 A JP2017568408 A JP 2017568408A JP 7068827 B2 JP7068827 B2 JP 7068827B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
cremisol
effective amount
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017568408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519340A5 (enExample
JP2018519340A (ja
Inventor
ジェフリー エス． グレン
エドワード エイ． ファム
Original Assignee
アイガー グループ インターナショナル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイガー グループ インターナショナル インコーポレイテッド filed Critical アイガー グループ インターナショナル インコーポレイテッド
Publication of JP2018519340A publication Critical patent/JP2018519340A/ja
Publication of JP2018519340A5 publication Critical patent/JP2018519340A5/ja
Priority to JP2022075974A priority Critical patent/JP7470151B2/ja
Application granted granted Critical
Publication of JP7068827B2 publication Critical patent/JP7068827B2/ja
Priority to JP2024061358A priority patent/JP7810746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017568408A 2015-06-30 2016-06-30 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用 Active JP7068827B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022075974A JP7470151B2 (ja) 2015-06-30 2022-05-02 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用
JP2024061358A JP7810746B2 (ja) 2015-06-30 2024-04-05 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187061P 2015-06-30 2015-06-30
US62/187,061 2015-06-30
PCT/US2016/040566 WO2017004454A1 (en) 2015-06-30 2016-06-30 Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022075974A Division JP7470151B2 (ja) 2015-06-30 2022-05-02 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用

Publications (3)

Publication Number Publication Date
JP2018519340A JP2018519340A (ja) 2018-07-19
JP2018519340A5 JP2018519340A5 (enExample) 2020-05-28
JP7068827B2 true JP7068827B2 (ja) 2022-05-17

Family

ID=57609247

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017568408A Active JP7068827B2 (ja) 2015-06-30 2016-06-30 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用
JP2022075974A Active JP7470151B2 (ja) 2015-06-30 2022-05-02 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用
JP2024061358A Active JP7810746B2 (ja) 2015-06-30 2024-04-05 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022075974A Active JP7470151B2 (ja) 2015-06-30 2022-05-02 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用
JP2024061358A Active JP7810746B2 (ja) 2015-06-30 2024-04-05 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用

Country Status (14)

Country Link
US (3) US10688083B2 (enExample)
EP (1) EP3317274A4 (enExample)
JP (3) JP7068827B2 (enExample)
KR (3) KR20230129590A (enExample)
CN (2) CN107922404B (enExample)
AU (4) AU2016288699B2 (enExample)
CA (3) CA3294570A1 (enExample)
HK (1) HK1249508A1 (enExample)
IL (4) IL300476B2 (enExample)
MX (3) MX394605B (enExample)
NZ (1) NZ776616A (enExample)
TW (3) TWI771272B (enExample)
WO (1) WO2017004454A1 (enExample)
ZA (2) ZA201708471B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022105149A (ja) * 2015-06-30 2022-07-12 アイガー グループ インターナショナル インコーポレイテッド 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
CN106831571A (zh) * 2017-02-13 2017-06-13 中卫市创科知识产权投资有限公司 一种硫酸氯喹生产工艺
CA3082591A1 (en) * 2017-11-15 2019-05-23 Beth Israel Deaconess Medical Center, Inc. Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途
WO2021217574A1 (en) * 2020-04-30 2021-11-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
CN111551645B (zh) * 2020-04-30 2022-11-08 上海中西三维药业有限公司 一种硫酸羟氯喹有关物质的检测方法及其应用
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111662229B (zh) * 2020-07-08 2023-03-24 精华制药集团南通有限公司 一种磷酸氯喹的制备工艺
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯（深圳）科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112225697B (zh) * 2020-10-16 2023-01-03 宁波大学 一种对映体纯氯喹及磷酸氯喹的制备方法
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN116327749A (zh) * 2023-04-21 2023-06-27 重庆医科大学 Gw9662制备治疗非酒精性脂肪性肝炎药物的应用
CN117466821A (zh) * 2023-10-25 2024-01-30 中化医药有限公司 一种盐酸克立咪唑的工艺制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509950A (ja) 2003-10-27 2007-04-19 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｈｃｖ処置の組合せ剤
JP2009526070A (ja) 2006-02-09 2009-07-16 シェーリング コーポレイション Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
WO2013177219A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
WO2013180149A1 (ja) 2012-05-30 2013-12-05 富山化学工業株式会社 重水素化含窒素複素環カルボキサミド誘導体またはその塩
JP2014097964A (ja) 2012-11-16 2014-05-29 Concert Pharmaceuticals Inc 重水素化されたｃｆｔｒ増強物質
JP2015117185A (ja) 2013-12-17 2015-06-25 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
WO1998017231A2 (en) 1996-10-18 1998-04-30 Charous B Lauren Treatment and delivery of hydroxychloroquine
CA2372443C (en) * 1999-04-30 2010-07-13 Apt Pharmaceuticals, L.L.C. Local administration of anti-malarial agents for the treatment of inflammatory diseases
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2003103586A2 (en) 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
TW200902047A (en) 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
ZA200505996B (en) * 2003-02-14 2006-12-27 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
AU2003219160A1 (en) * 2003-03-12 2004-09-30 Molecular Engines Laboratories Sa Methods and compositions for the treatment of cancer
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CN101193622A (zh) 2005-06-09 2008-06-04 比奥里波克斯公司 治疗炎性疾病的方法和组合物
EP1888033B1 (en) * 2005-06-09 2014-02-19 Meda AB Method and composition for treating inflammatory disorders
WO2009039248A2 (en) * 2007-09-18 2009-03-26 Stanford University Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
EP2188630A4 (en) * 2007-10-02 2010-11-03 Univ Rochester METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC ANSWERS TO ONCOGENIC MUTATIONS
US20120114670A1 (en) 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
HUE052510T2 (hu) * 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
CN102548393B (zh) * 2009-07-31 2015-06-03 斯特里克再生医学学院,斯特里克学院事务所 脂肪性肝炎-肝癌模型动物
KR20180036810A (ko) * 2009-08-14 2018-04-09 레비비코르 인코포레이션 당뇨병 치료를 위한 복수 형질전환 돼지
US9415046B2 (en) * 2009-09-29 2016-08-16 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
US20120202849A1 (en) 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
US9700560B2 (en) * 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CA2848711C (en) * 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
EP2818473A4 (en) * 2012-02-20 2015-04-15 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
US20130273003A1 (en) * 2012-04-17 2013-10-17 Vertex Pharmaceuticals Incorporated Therapies for Treating Hepatitis C Virus Infection
WO2014031769A2 (en) 2012-08-21 2014-02-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases associated with inflammation
CN103550242B (zh) 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
JP2017504572A (ja) * 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
CA3294570A1 (en) * 2015-06-30 2026-03-02 Eiger Group International, Inc. Use of r-chloroquine or metabolites, r-rhydroxychloroquine or metabolites, or deuterated analogs of r-chloroquine or rhydroxychloroquine, in treatment of liver inflammation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509950A (ja) 2003-10-27 2007-04-19 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｈｃｖ処置の組合せ剤
JP2009526070A (ja) 2006-02-09 2009-07-16 シェーリング コーポレイション Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
WO2013177219A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
WO2013180149A1 (ja) 2012-05-30 2013-12-05 富山化学工業株式会社 重水素化含窒素複素環カルボキサミド誘導体またはその塩
JP2014097964A (ja) 2012-11-16 2014-05-29 Concert Pharmaceuticals Inc 重水素化されたｃｆｔｒ増強物質
JP2015117185A (ja) 2013-12-17 2015-06-25 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Viruses，2010年，Vol.2，p.2481-2492

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022105149A (ja) * 2015-06-30 2022-07-12 アイガー グループ インターナショナル インコーポレイテッド 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用
JP7470151B2 (ja) 2015-06-30 2024-04-17 アイガー グループ インターナショナル インコーポレイテッド 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用

Also Published As

Publication number Publication date
IL310969A (en) 2024-04-01
WO2017004454A8 (en) 2018-01-25
KR20230129590A (ko) 2023-09-08
JP2024083475A (ja) 2024-06-21
EP3317274A1 (en) 2018-05-09
MX2022008100A (es) 2022-07-11
AU2016288699A1 (en) 2018-01-18
TWI830262B (zh) 2024-01-21
US12090141B2 (en) 2024-09-17
MX2017016681A (es) 2018-07-06
US20240398761A1 (en) 2024-12-05
AU2023201397B2 (en) 2024-10-03
KR20180032578A (ko) 2018-03-30
JP2022105149A (ja) 2022-07-12
TW202402283A (zh) 2024-01-16
KR20260077866A (ko) 2026-05-28
US20180200228A1 (en) 2018-07-19
CA2989634A1 (en) 2017-01-05
IL279020B1 (en) 2023-03-01
US20210052553A1 (en) 2021-02-25
IL300476A (en) 2023-04-01
BR112017028601A2 (pt) 2018-08-28
NZ738291A (en) 2021-06-25
IL279020B2 (en) 2023-07-01
AU2024266943A1 (en) 2024-12-19
CN113274386A (zh) 2021-08-20
WO2017004454A1 (en) 2017-01-05
CA3178499C (en) 2026-05-12
ZA202004136B (en) 2025-08-27
IL300476B1 (en) 2024-03-01
CA3178499A1 (en) 2017-01-05
CN107922404B (zh) 2021-06-29
HK1249508A1 (zh) 2018-11-02
TWI881480B (zh) 2025-04-21
CA2989634C (en) 2022-12-06
TW202317103A (zh) 2023-05-01
MX394605B (es) 2025-03-24
TWI771272B (zh) 2022-07-21
EP3317274A4 (en) 2019-05-08
IL279020A (enExample) 2020-12-31
AU2021201234A1 (en) 2021-03-11
CN107922404A (zh) 2018-04-17
AU2023201397A1 (en) 2023-04-06
JP2018519340A (ja) 2018-07-19
JP7810746B2 (ja) 2026-02-03
CA3294570A1 (en) 2026-03-02
US10688083B2 (en) 2020-06-23
TW201717941A (zh) 2017-06-01
JP7470151B2 (ja) 2024-04-17
ZA201708471B (en) 2022-05-25
NZ776616A (en) 2024-11-29
MX2023003792A (es) 2023-04-26
IL256233A (en) 2018-02-28
AU2016288699B2 (en) 2020-11-26
IL300476B2 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
JP7810746B2 (ja) 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用
CN111658659B (zh) 用于在预防和/或治疗缺血性脑血管疾病中使用的治疗剂
KR20180051430A (ko) 8-히드록시 퀴놀린 유도체의 에난티오머 및 그의 합성
CA2911307C (en) Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
NZ738291B2 (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
BR112017028601B1 (pt) Uso de clemizol
KR101512486B1 (ko) 피리피로펜 ｓ 및 그의 제조방법
JP2026508302A (ja) ヒドロキシアルキルおよびメトキシアルキルトリプタミン
JP2004292366A (ja) １，２−ジオキサン化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200413

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200413

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210311

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220502

R150 Certificate of patent or registration of utility model

Ref document number: 7068827

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250